PL1979356T3 - Karbonyloaminopirolopirazole, inhibitory kinazy białkowej - Google Patents

Karbonyloaminopirolopirazole, inhibitory kinazy białkowej

Info

Publication number
PL1979356T3
PL1979356T3 PL06831731T PL06831731T PL1979356T3 PL 1979356 T3 PL1979356 T3 PL 1979356T3 PL 06831731 T PL06831731 T PL 06831731T PL 06831731 T PL06831731 T PL 06831731T PL 1979356 T3 PL1979356 T3 PL 1979356T3
Authority
PL
Poland
Prior art keywords
pyrrolopyrazoles
carbonylamino
kinase inhibitors
potent kinase
potent
Prior art date
Application number
PL06831731T
Other languages
English (en)
Inventor
Liming Dong
Chuangxing Guo
Yufeng Hong
Mary Catherine Johnson
Susan Elizabeth Kephart
Haitao Li
Indrawan James Mcalpine
Jayashree Girish Tikhe
Anle Yang
Junhu Zhang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL1979356T3 publication Critical patent/PL1979356T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL06831731T 2005-12-21 2006-12-12 Karbonyloaminopirolopirazole, inhibitory kinazy białkowej PL1979356T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
EP06831731.2A EP1979356B1 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (1)

Publication Number Publication Date
PL1979356T3 true PL1979356T3 (pl) 2014-01-31

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06831731T PL1979356T3 (pl) 2005-12-21 2006-12-12 Karbonyloaminopirolopirazole, inhibitory kinazy białkowej

Country Status (27)

Country Link
US (1) US7884117B2 (pl)
EP (1) EP1979356B1 (pl)
JP (1) JP4635089B2 (pl)
KR (1) KR101029167B1 (pl)
AP (1) AP2369A (pl)
AU (1) AU2006327866B2 (pl)
BR (1) BRPI0620354A2 (pl)
CA (1) CA2634381C (pl)
CR (1) CR10094A (pl)
CU (1) CU23751B7 (pl)
DK (1) DK1979356T3 (pl)
EA (1) EA015513B1 (pl)
EC (1) ECSP088558A (pl)
ES (1) ES2435405T3 (pl)
GE (1) GEP20104974B (pl)
HK (1) HK1128290A1 (pl)
HR (1) HRP20130976T1 (pl)
IL (1) IL191776A (pl)
MA (1) MA30076B1 (pl)
ME (1) MEP0808A (pl)
MY (1) MY151455A (pl)
NO (1) NO20082482L (pl)
NZ (1) NZ568692A (pl)
PL (1) PL1979356T3 (pl)
PT (1) PT1979356E (pl)
RS (2) RS53029B (pl)
WO (1) WO2007072153A2 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
IN2012DN00720A (pl) 2009-07-06 2015-06-19 Ontorii Inc
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
DK2620428T3 (da) * 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
EP2640369A1 (en) 2010-11-17 2013-09-25 F.Hoffmann-La Roche Ag Methods of treating tumors
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 官能化核酸の合成のための方法
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
CN104168898A (zh) 2012-03-16 2014-11-26 霍夫曼-拉罗奇有限公司 以pak1抑制剂治疗黑色素瘤的方法
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR20220106232A (ko) 2014-01-16 2022-07-28 웨이브 라이프 사이언시스 리미티드 키랄 디자인
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
KR102575327B1 (ko) 2014-10-31 2023-09-07 유비이 가부시키가이샤 치환 디히드로피롤로피라졸 화합물
WO2016105528A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
MX2017016030A (es) 2015-06-15 2018-08-01 Ube Industries Derivado de dihidropirrolopirazol sustituido.
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
WO2020100944A1 (ja) 2018-11-14 2020-05-22 宇部興産株式会社 ジヒドロピロロピラゾール誘導体
JP2022517740A (ja) * 2018-12-28 2022-03-10 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼ7のインヒビターおよびそれらの使用
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200301813B (en) 2000-08-10 2004-06-22 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
US20060135508A1 (en) 2002-07-25 2006-06-22 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
ATE546452T1 (de) 2003-09-23 2012-03-15 Vertex Pharma Pyrazolopyrrolderivate als proteinkinaseinhibitoren
ES2365245T3 (es) * 2005-01-10 2011-09-27 Pfizer, Inc. Pirrolopirazoles, potentes inhibidores de quinasas.

Also Published As

Publication number Publication date
AU2006327866B2 (en) 2012-06-14
WO2007072153A3 (en) 2007-10-25
PT1979356E (pt) 2013-11-21
HRP20130976T1 (hr) 2013-11-22
ES2435405T3 (es) 2013-12-19
AU2006327866A1 (en) 2007-06-28
NZ568692A (en) 2011-07-29
KR101029167B1 (ko) 2011-04-12
BRPI0620354A2 (pt) 2011-11-08
US7884117B2 (en) 2011-02-08
CA2634381A1 (en) 2007-06-28
MA30076B1 (fr) 2008-12-01
IL191776A (en) 2013-03-24
JP2009520805A (ja) 2009-05-28
KR20080080567A (ko) 2008-09-04
CU20080115A7 (es) 2010-08-30
ECSP088558A (es) 2008-07-30
JP4635089B2 (ja) 2011-02-16
AP2008004506A0 (en) 2008-06-30
CU23751B7 (es) 2012-01-31
EA015513B1 (ru) 2011-08-30
WO2007072153A2 (en) 2007-06-28
WO2007072153A8 (en) 2008-08-14
ME00006B (me) 2010-02-10
MEP0808A (xx) 2010-02-10
AP2369A (en) 2012-02-29
RS53029B (en) 2014-04-30
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
US20090318440A1 (en) 2009-12-24
DK1979356T3 (da) 2013-11-18
HK1128290A1 (en) 2009-10-23
GEP20104974B (en) 2010-04-26
MY151455A (en) 2014-05-30
EA200801291A1 (ru) 2008-12-30
EP1979356B1 (en) 2013-09-18
RS20080281A (en) 2009-09-08
NO20082482L (no) 2008-07-02
IL191776A0 (en) 2008-12-29
CA2634381C (en) 2011-03-08

Similar Documents

Publication Publication Date Title
IL191776A0 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
AP2007004061A0 (en) Pyrrolopyrazoles, potent kinase inhibitors
IL190078A0 (en) Kinase inhibitors
GB2424882B (en) Selective kinase inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
IL187881A0 (en) Sphingosine kinase inhibitors
PL1943243T3 (pl) Inhibitory kinazy
IL183276A0 (en) Kinase inhibitors
EP1968581A4 (en) TETRACYCLIC KINASE INHIBITORS
HK1100141A1 (en) Kinase inhibitors
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
ZA200804667B (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
GB0608854D0 (en) P13 kinase inhibitors
GB0516967D0 (en) Inhibitors
IL189985A0 (en) Kinase inhibitors
ZA200803287B (en) Kinase inhibitors
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
GB0506443D0 (en) Novel inhibitors